1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BD68ACE5AC94DFB4652580D1001D52B0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/benchmarking-field-medical-outcomes-pricing-kol-engagement-strategies?opendocument
18
19opendocument
203.91.106.44
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Science Liaison

Benchmarking Field Medical & Field Outcomes and Pricing KOL Engagement Strategies

ID: POP-288


Features:

6 Info Graphics

24 Data Graphics

217 Metrics


Pages: 37


Published: 2017


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The growing demand for scientific and medical data in the biopharmaceutical industry has pushed organizations to develop effective KOL engagement strategies for their field-based medical and field-based outcomes and pricing group.

This benchmarking report examines current industry trends and best practices for field-based medical and field-based outcomes and pricing teams in North America, Europe, APAC and Emerging Markets. In particular, this research establishes benchmarks around virtual HCP engagement; field medical team deployment and reporting relationships; and activity levels and product coverage.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
Avanir; Boehringer Ingelheim; Galderma; GlaxoSmithKline ; Janssen; Medtronic; Merck; QuintilesIMS; Roche; Sanofi; Sunovion; Takeda Pharmaceuticals; Tide Pharmaceutical Company; UCB Pharma; ViiV Healthcare

Study Snapshot

Best Practices, LLC engaged 17 leaders with direct experience working with field medical and field outcomes and pricing teams from 15 leading bio-pharmaceutical companies through a benchmarking survey instrument. More than half of the benchmark class are at the level of director or above.

Key Findings

  • About a Quarter of Field Interactions are Conducted Virtually: Close to 15% of the benchmark class conducts one to one field engagement virtually. About 12% of the benchmark class conducts one to many (remote presentation) engagement virtually with the field teams.
  • Field Medical Team Presence Tapers Three Years Post Launch: Field medical teams are first deployed at the End of Phase II at 38% of the participating companies, while their presence peaks during the launch year within 36% of the benchmark class. The presence of field medical teams tapers three years post launch at 64% of the participating companies.

Table of Contents

I.Executive Summarypgs. 3-8
Research Overviewpg. 3
Participating Companiespg. 4
Overview of Findingspg. 5
Key Findingspgs. 6-8
II.In-Person vs. Virtual HCP Engagementpgs. 9-11
III.Structure and Leadershippgs. 12-21
IV.Activity Levels and Product Coveragepgs. 22-35
V.About Best Practices, LLCpgs. 36-37

    List of Charts & Exhibits

    • Proportion of Field Interactions Conducted Virtually
    • Satisfaction/Impact Levels when Using Technology vs. In-Person Meetings
    • Field Medical Team Deployment during Each Phase
    • Are Strategic Goals Driver of Time and Volume of MSL deployment?
    • Field Medical Team Reporting Relationship in North America, Europe, APAC and Emerging Markets
    • Do you have a Separate Field Outcomes & Pricing Group or is it Rolled into Field Medical Responsibilities?
    • Do you have an Established Weekly, Monthly, Quarterly or Annual MSL Thought Leader Engagement Activity Level?
    • Size of Medical Expert / Opinion Leader Panel with Which High Performing Field Medical Staff Regularly Engage (On a Per Employee Basis)
    • Number of Products Currently in the Market Actively Supported per Field Medical Employee
    • Number of Products in the Development Pipeline Actively Supported per Field Medical Employee
    • Field Medical Therapeutic Area Coverage
    • Whether Form 2253 is Filed for Proactive Resources Used by MSL Team?